March 12 (Reuters) - The U.S. health regulator's staff
on Tuesday flagged concerns that the late-stage trial data on
Geron's ( GERN ) anemia drug does not show whether the risks of
treatment with imetelstat are outweighed by the potential
benefit, documents released ahead of a meeting of independent
experts showed.